Frontiers in Oncology · 8 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This systematic review and meta-analysis of three randomized trials found that adding zolbetuximab to first-line chemotherapy significantly improved overall and progression-free survival for patients with advanced Claudin 18.2-positive gastric or gastro-esophageal junction adenocarcinoma compared to chemotherapy alone.
Subgroup analysis showed a more significant benefit for patients with high Claudin 18.2 expression. Regarding safety, the combination therapy was associated with a higher risk of grade 3 or higher adverse events, particularly nausea and vomiting. Limitations include the small number of included studies and the need for further data on adverse event profiles.
